- Conditions
- Prostate Cancer
- Interventions
- perifosine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 5,944
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
- Interventions
- Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Placebo Administration, Sargramostim
- Drug · Other · Biological
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Cenerimod, Placebo
- Drug
- Lead sponsor
- Viatris Innovation GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 22
- States / cities
- Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more
- Conditions
- Breast Cancer
- Interventions
- erlotinib hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Osteoporosis
- Interventions
- zoledronic acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 45 Years to 79 Years · Female only
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 12
- States / cities
- Santa Rosa, California • Lakewood, Colorado • Gainsville, Florida + 9 more
- Conditions
- Cardiovascular Disease, Periodontal Disease
- Interventions
- Early Periodontal Treatment, Usual Dental Hygiene
- Procedure
- Lead sponsor
- Boston University
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- etoposide, topotecan hydrochloride
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Baltimore, Maryland • Camden, New Jersey + 2 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Tadalafil, Placebo
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 9
- States / cities
- Portland, Maine • Boston, Massachusetts • Newark, New Jersey + 4 more
- Conditions
- Edentulism, Alveolar Bone Atrophy, Sinus Pneumatization
- Interventions
- Sinus grafting using allogenic bone
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Peri-Implantitis
- Interventions
- Membrane placement with bone grafting
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- HIV Infections, Pregnancy
- Interventions
- Indinavir sulfate, Lamivudine, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2003
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • The Bronx, New York
- Conditions
- COVID-19
- Interventions
- Merimepodib, Matching Placebo, Remdesivir
- Drug
- Lead sponsor
- ViralClear Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Fort Lauderdale, Florida • Jacksonville, Florida + 6 more
- Conditions
- Squamous Cell Carcinoma, Oral Cancer
- Interventions
- Docetaxel, Cisplatin, 5-fluorouracil
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Systemic Sclerosis
- Interventions
- treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan
- Conditions
- Fabry Disease
- Interventions
- Lucerastat, Placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Irvine, California • Oakland, California + 14 more
- Conditions
- Gingivitis
- Interventions
- Stannous Fluoride Dentifrice, Test Stannous Fluoride Dentifrice, Sodium monofluorophosphate dentifrice
- Drug
- Lead sponsor
- Procter and Gamble
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Whitter, California
- Conditions
- Opioid Use Disorder
- Interventions
- CVL-354, [11C]-LY2795050, [11C]-carfentanil
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Cataract, Bilateral Senile Cataract, Anesthesia, Patient Satisfaction
- Interventions
- Oral sedation, Placebo
- Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- Voriconazole, Liposomal amphotericin B
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Oropharynx Cancer, Head and Neck Cancer, Xerostomia
- Interventions
- standard radiotherapy, experimental radiotherapy
- Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Type 2 Diabetes
- Interventions
- Hypoxico Altitude Training Systems
- Device
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- GSK2256294
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hepatitis C, Cryoglobulinemia
- Interventions
- Harvoni, Epclusa
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hormone Receptor Positive Early Breast Cancer
- Interventions
- US-sourced oral Femara® + Letrozole SIE, EU sourced oral Femara® + Letrozole SIE
- Drug
- Lead sponsor
- Rovi Pharmaceuticals Laboratories
- Industry
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Margate, Florida • Port Orange, Florida